Akinori Asagi

Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial

Chigusa Morizane, Takuji Okusaka, Junki Mizusawa et al. · Annals of Oncology · 2019 · 334 citations

Medicine, Oncology, Chemotherapy +7

Utility of Contrast-Enhanced FDG-PET/CT in the Clinical Management of Pancreatic Cancer

Akinori Asagi, Koji Ohta, Junichirou Nasu et al. · Pancreas · 2012 · 129 citations

Medicine, Nuclear Medicine, Radiology +17

Evaluation of safety and tolerability of durvalumab (D) with or without tremelimumab (T) in patients (pts) with biliary tract cancer (BTC).

Tatsuya Ioka, Makoto Ueno, Do‐Youn Oh et al. · Journal of Clinical Oncology · 2019 · 113 citations

Pharmacy, Oncology, Pharmacotherapy +17

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma et al. · JAMA Oncology · 2022 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma

Satoshi Kobayashi, Takeshi Terashima, Satoshi Shiba et al. · Cancer Science · 2018 · 79 citations · Full text

Medicine, Oncology, Pathology +17